Skip to content

Study · Animal study (in vivo) · rat · 2023

14 results

Abaloparatide outperforms teriparatide in protecting against alveolar bone loss in experimental periodontitis.

Li Y, Qian Y, Qiao H, Pan W, Xie L, Li Y

Journal of periodontology8 Nov 2022Cited by 11 (Europe PMC)

PMID35892139 (opens in a new tab)DOI10.1002/jper.22-0211 (opens in a new tab)PepBankPUB-35892139
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, abaloparatide significantly reduced alveolar bone loss compared with saline.

    In plain wordsIn rats with periodontitis, abaloparatide reduced alveolar bone loss compared with saline.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseAlveolar bone loss
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Comparator
    saline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    On the ligature side, both ABL and TPTD significantly reduced alveolar bone loss
    1 context sentence
    Summary · context
    Twenty-four 9-week-old, male, Sprague-Dawley rats were placed with silk suture around the right maxillary second molar, and then were randomly divided into three groups, that is, the ABL, TPTD, and saline group, receiving intermittent subcutaneous injections of ABL (80 μg/kg), TPTD (80 μg/kg) or sal…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, teriparatide significantly reduced alveolar bone loss compared with saline.

    In plain wordsIn rats with periodontitis, teriparatide reduced alveolar bone loss compared with saline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseAlveolar bone loss
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Comparator
    saline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    On the ligature side, both ABL and TPTD significantly reduced alveolar bone loss
    1 context sentence
    Summary · context
    Twenty-four 9-week-old, male, Sprague-Dawley rats were placed with silk suture around the right maxillary second molar, and then were randomly divided into three groups, that is, the ABL, TPTD, and saline group, receiving intermittent subcutaneous injections of ABL (80 μg/kg), TPTD (80 μg/kg) or sal…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, abaloparatide provided significantly better alveolar bone protection than teriparatide.

    In plain wordsIn rats with periodontitis, abaloparatide protected alveolar bone more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAlveolar bone protection
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    On the ligature side, both ABL and TPTD significantly reduced alveolar bone loss, and ABL had significantly better effects with higher expression of runt-related transcription factor 2 (RUNX2) and Bglap (formerly called osteocalcin)
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, abaloparatide produced higher RUNX2 expression than teriparatide.

    In plain wordsIn rats with periodontitis, abaloparatide produced higher RUNX2 expression than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseRUNX2 expression
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    On the ligature side, both ABL and TPTD significantly reduced alveolar bone loss, and ABL had significantly better effects with higher expression of runt-related transcription factor 2 (RUNX2) and Bglap (formerly called osteocalcin)
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, abaloparatide produced higher Bglap expression than teriparatide.

    In plain wordsIn rats with periodontitis, abaloparatide produced higher Bglap expression than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBglap expression
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    On the ligature side, both ABL and TPTD significantly reduced alveolar bone loss, and ABL had significantly better effects with higher expression of runt-related transcription factor 2 (RUNX2) and Bglap (formerly called osteocalcin)
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, abaloparatide did not affect ligature-induced osteoclastogenesis.

    In plain wordsIn rats with periodontitis, abaloparatide did not change ligature-induced osteoclast formation.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeOsteoclastogenesis
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    meanwhile, the ligature induced osteoclastogenesis and down-regulation of osteoprotegerin (OPG) was affected by neither drug.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, teriparatide did not affect ligature-induced osteoclastogenesis.

    In plain wordsIn rats with periodontitis, teriparatide did not change ligature-induced osteoclast formation.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOsteoclastogenesis
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    meanwhile, the ligature induced osteoclastogenesis and down-regulation of osteoprotegerin (OPG) was affected by neither drug.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, abaloparatide did not affect ligature-induced OPG down-regulation.

    In plain wordsIn rats with periodontitis, abaloparatide did not change the ligature-induced decrease in OPG.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeOPG down-regulation
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    meanwhile, the ligature induced osteoclastogenesis and down-regulation of osteoprotegerin (OPG) was affected by neither drug.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with periodontitis, teriparatide did not affect ligature-induced OPG down-regulation.

    In plain wordsIn rats with periodontitis, teriparatide did not change the ligature-induced decrease in OPG.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOPG down-regulation
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    meanwhile, the ligature induced osteoclastogenesis and down-regulation of osteoprotegerin (OPG) was affected by neither drug.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    On the non-ligature side in rats, abaloparatide showed better osteoanabolic effects than teriparatide.

    In plain wordsIn rats, abaloparatide showed better bone-building effects than teriparatide on the side without a ligature.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseNon-ligature osteoanabolic effects
    Study

    ratn: not reported in source

    ligature-induced periodontitis
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg every other day · subcutaneous · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    On the non-ligature side, ABL also showed better osteoanabolic effects.
    1 context sentence
    Summary · context
    The aim of this study was to compare the effects of two osteoanabolic drugs, abaloparatide (ABL) and teriparatide (TPTD), on protecting alveolar bone in experimental periodontitis.
  11. 11LabIn vitro (cells)Efficacy outcome

    In LPS-treated MC3T3 cells, abaloparatide promoted proliferation similarly to teriparatide.

    In plain wordsIn cells exposed to LPS, abaloparatide promoted proliferation similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseMC3T3 proliferation
    Study

    mousen: not reported in source

    LPS-treated MC3T3 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro studies revealed that, in the presence of LPS, ABL, and TPTD similarly promoted MC3T3 proliferation, whereas ABL induced higher ALP activity and osteoblastic gene expression compared to TPTD.
    1 context sentence
    Summary · context
    Mouse pre-osteoblast MC3T3 cell was cultured with lipopolysaccharide (LPS) and treated with ABL or TPTD, before assays of cell proliferation, alkaline phosphatase (ALP) activity and real-time polymerase chain reaction.
  12. 12LabIn vitro (cells)Efficacy outcome

    In LPS-treated MC3T3 cells, teriparatide promoted proliferation similarly to abaloparatide.

    In plain wordsIn cells exposed to LPS, teriparatide promoted proliferation similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMC3T3 proliferation
    Study

    mousen: not reported in source

    LPS-treated MC3T3 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro studies revealed that, in the presence of LPS, ABL, and TPTD similarly promoted MC3T3 proliferation, whereas ABL induced higher ALP activity and osteoblastic gene expression compared to TPTD.
    1 context sentence
    Summary · context
    Mouse pre-osteoblast MC3T3 cell was cultured with lipopolysaccharide (LPS) and treated with ABL or TPTD, before assays of cell proliferation, alkaline phosphatase (ALP) activity and real-time polymerase chain reaction.
  13. 13LabIn vitro (cells)Efficacy outcome

    In LPS-treated MC3T3 cells, abaloparatide induced higher ALP activity than teriparatide.

    In plain wordsIn cells exposed to LPS, abaloparatide increased ALP activity more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseALP activity
    Study

    mousen: not reported in source

    LPS-treated MC3T3 cells
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro studies revealed that, in the presence of LPS, ABL, and TPTD similarly promoted MC3T3 proliferation, whereas ABL induced higher ALP activity and osteoblastic gene expression compared to TPTD.
    1 context sentence
    Summary · context
    Mouse pre-osteoblast MC3T3 cell was cultured with lipopolysaccharide (LPS) and treated with ABL or TPTD, before assays of cell proliferation, alkaline phosphatase (ALP) activity and real-time polymerase chain reaction.
  14. 14LabIn vitro (cells)Efficacy outcome

    In LPS-treated MC3T3 cells, abaloparatide induced higher osteoblastic gene expression than teriparatide.

    In plain wordsIn cells exposed to LPS, abaloparatide increased bone-forming gene expression more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteoblastic gene expression
    Study

    mousen: not reported in source

    LPS-treated MC3T3 cells
    Comparator
    teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro studies revealed that, in the presence of LPS, ABL, and TPTD similarly promoted MC3T3 proliferation, whereas ABL induced higher ALP activity and osteoblastic gene expression compared to TPTD.
    1 context sentence
    Summary · context
    Mouse pre-osteoblast MC3T3 cell was cultured with lipopolysaccharide (LPS) and treated with ABL or TPTD, before assays of cell proliferation, alkaline phosphatase (ALP) activity and real-time polymerase chain reaction.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06061354

Teriparatide on Maxillary Sinus Floor Osseointegration

Universidad de Valparaison = 4223 Aug 2023 to est. Dec 2024

Bone Regeneration

Trial pageClinicalTrials.govUpdated 30 Nov 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.